Table 1.
Comparison of baseline patient characteristics before and after matching
| Description | Pre‐match | Post‐match | ||||
|---|---|---|---|---|---|---|
| ARNI | No ARNI | Standardized difference (%) | ARNI | No ARNI | Standardized difference (%) | |
| N | 746 | 3184 | 576 | 1152 | ||
| Sociodemographic | ||||||
| Age | 63.4 (13.0) | 67.3 (12.3) | 30.4 | 64.7 (13.2) | 65.7 (12.5) | 8.2 |
| Female | 29% (217) | 29% (923) | 0.2 | 30% (173) | 27% (310) | 6.9 |
| White race | 75% (559) | 74% (2348) | 2.7 | 76% (437) | 74% (854) | 4.0 |
| Hispanic | 11% (83) | 20% (652) | 25.9 | 12% (67) | 12% (133) | 0.3 |
| Low income (<$25 K) | 38% (285) | 42% (1326) | 7.0 | 37% (214) | 39% (454) | 4.6 |
| Working FT/PT | 26% (195) | 20% (640) | 14.4 | 25% (143) | 24% (279) | 1.4 |
| Clinical measures | ||||||
| BMI | 31.3 (7.3) | 30.1 (7.2) | 15.7 | 31.0 (7.4) | 30.4 (7.4) | 9.1 |
| Systolic BP | 119.9 (17.1) | 122.0 (17.8) | 11.5 | 121.1 (18.1) | 119.8 (17.8) | 7.4 |
| Heart rate | 74.0 (12.7) | 74.0 (12.5) | 0.0 | 74.4 (12.9) | 73.9 (12.7) | 3.8 |
| LVEF | 27.8 (7.8) | 30.2 (7.7) | 30.9 | 30.1 (7.0) | 30.0 (9.0) | 2.0 |
| Medical history | ||||||
| History AF/flutter | 36% (271) | 36% (1150) | 0.4 | 38% (218) | 38% (441) | 0.9 |
| History VT/VF | 25% (183) | 18% (568) | 16.4 | 26% (149) | 24% (276) | 4.4 |
| CRT | 9% (67) | 6% (204) | 9.7 | 11% (61) | 10% (113) | 2.6 |
| Lung disease | 27% (202) | 33% (1036) | 12.0 | 29% (169) | 29% (331) | 1.3 |
| CAD | 61% (458) | 66% (2101) | 9.6 | 63% (361) | 66% (765) | 7.8 |
| Diabetes | 42% (310) | 42% (1342) | 1.2 | 44% (253) | 39% (455) | 9.0 |
| Depression or anxiety | 34% (250) | 36% (1133) | 4.4 | 36% (206) | 36% (420) | 1.4 |
| Hypertension | 83% (617) | 85% (2716) | 7.1 | 83% (480) | 83% (958) | 0.5 |
| Ischaemic HF | 38% (281) | 41% (1303) | 6.7 | 39% (224) | 42% (488) | 7.1 |
| Current smoker | 21% (159) | 20% (633) | 3.5 | 22% (125) | 21% (244) | 1.3 |
| Prior HF hospitalization | 38% (280) | 37% (1172) | 1.5 | 41% (235) | 45% (515) | 7.9 |
| CKD | 19% (143) | 22% (691) | 6.3 | 20% (113) | 21% (240) | 3.0 |
| Medications | ||||||
| ACEi/ARB | 65% (487) | 79% (2529) | 32.0 | 49% (284) | 49% (568) | 0.0 |
| Beta‐blocker | 96% (719) | 90% (2853) | 26.8 | 97% (556) | 97% (1116) | 1.9 |
| MRA | 47% (347) | 32% (1024) | 29.7 | 47% (270) | 44% (505) | 6.1 |
| Loop diuretic | 72% (537) | 63% (1991) | 20.2 | 73% (418) | 70% (812) | 4.6 |
| Hydralazine | 4% (29) | 6% (185) | 9.0 | 5% (27) | 3% (40) | 6.1 |
| Digoxin | 18% (134) | 13% (413) | 13.8 | 17% (99) | 15% (178) | 4.7 |
| Ivabradine | 1% (11) | 1% (32) | 4.2 | 1% (6) | 2% (20) | 5.9 |
| KCCQ scores | ||||||
| Overall score | 64.1 (23.6) | 65.0 (23.6) | 3.5 | 66.9 (23.2) | 69.2 (23.3) | 9.9 |
| Symptom frequency | 68.4 (25.6) | 69.9 (25.0) | 6.1 | 70.6 (25.4) | 73.5 (24.5) | 11.6 |
| QOL | 56.8 (28.6) | 58.5 (28.1) | 6.0 | 59.1 (27.7) | 62.6 (27.3) | 12.4 |
| Social limitations | 65.9 (29.1) | 67.7 (29.1) | 6.3 | 69.8 (28.1) | 72.2 (28.3) | 8.6 |
| Physical limitations | 65.1 (26.0) | 63.8 (27.5) | 5.1 | 67.7 (26.5) | 68.3 (26.8) | 2.0 |
ACEi, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CKD, chronic kidney disease; CRT, cardiac resynchronization therapy; HF, heart failure; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; QOL, quality of life; VF, ventricular fibrillation; VT, ventricular tachycardia.